Nevertheless, the use of either CCL2 or CCR2 inhibitors, in clinical trials, gave disappointing results, indicating the need of supplementary studies considering the presence of potential TME-dependent compensatory mechanisms acting on tumor-resident myeloid cells (146, 147). This evidence concerns the gene CCR2 and neoplasm.